GlycoMimetics Beheer
Beheer criteriumcontroles 2/4
De CEO GlycoMimetics is Harout Semerjian, benoemd in Aug2021, heeft een ambtstermijn van 3.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.39M, bestaande uit 26.7% salaris en 73.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.039% van de aandelen van het bedrijf, ter waarde $ 8.00K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.4 jaar en 8.2 jaar.
Belangrijke informatie
Harout Semerjian
Algemeen directeur
US$2.4m
Totale compensatie
| Percentage CEO-salaris | 26.7% |
| Dienstverband CEO | 3.3yrs |
| Eigendom CEO | 0.04% |
| Management gemiddelde ambtstermijn | 4.4yrs |
| Gemiddelde ambtstermijn bestuur | 8.2yrs |
Recente managementupdates
Recent updates
We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate
Jun 27
GlycoMimetics Can Become A Game Changer In Blood Cancers
Mar 21Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Mar 20GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real
Jan 30Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Nov 19Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?
Jan 30Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely
Oct 06GlycoMimetics has a new Chief Medical Officer
Sep 06GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K
Aug 03GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely
Jun 04GlycoMimetics Positive Data For AML Therapy Increasingly Likely
Mar 16Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Nov 20We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully
Aug 20GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study
May 26Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year
May 12GlycoMimetics EPS beats by $0.04
May 03Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Mar 26GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares
Feb 19GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings
Jan 24How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?
Dec 28New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease
Dec 07Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Dec 07The Investment Case For GlycoMimetics
Nov 17Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$40m |
| Jun 30 2024 | n/a | n/a | -US$39m |
| Mar 31 2024 | n/a | n/a | -US$37m |
| Dec 31 2023 | US$2m | US$638k | -US$37m |
| Sep 30 2023 | n/a | n/a | -US$38m |
| Jun 30 2023 | n/a | n/a | -US$37m |
| Mar 31 2023 | n/a | n/a | -US$42m |
| Dec 31 2022 | US$1m | US$614k | -US$47m |
| Sep 30 2022 | n/a | n/a | -US$54m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$64m |
| Dec 31 2021 | US$3m | US$244k | -US$63m |
Compensatie versus markt: De totale vergoeding ($USD 2.39M ) Harout } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.80K ).
Compensatie versus inkomsten: De vergoeding van Harout is gestegen terwijl het bedrijf verliesgevend is.
CEO
Harout Semerjian (54 yo)
3.3yrs
Tenure
US$2,389,418
Compensatie
Mr. Harout Semerjian serves as Chief Executive Officer, President & Director of GlycoMimetics, Inc., since August 6, 2021. He served as President and Chief Executive Officer of Immunomedics Inc. since Apri...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 3.3yrs | US$2.39m | 0.039% $ 8.0k | |
| Co-Founder & Director | 21.8yrs | US$96.00k | 0.98% $ 203.2k | |
| Senior VP & CFO | 12.8yrs | US$1.30m | 0.096% $ 19.8k | |
| Vice President of Accounting | 5.8yrs | geen gegevens | geen gegevens | |
| General Counsel & Company Secretary | 5.6yrs | geen gegevens | geen gegevens | |
| Senior VP & Chief Commercial Officer | 2.8yrs | geen gegevens | 0.22% $ 44.5k | |
| Senior VP & Chief Business Officer | 1.8yrs | geen gegevens | 0.25% $ 51.6k | |
| Senior Vice President of Technical Operations | less than a year | geen gegevens | geen gegevens |
4.4yrs
Gemiddelde duur
53.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van GLYC wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 3.3yrs | US$2.39m | 0.039% $ 8.0k | |
| Co-Founder & Director | 21.8yrs | US$96.00k | 0.98% $ 203.2k | |
| Independent Director | 8.7yrs | US$118.50k | 0.15% $ 31.5k | |
| Independent Chairman of the Board | 10.7yrs | US$138.00k | 0.038% $ 7.9k | |
| Independent Director | 7.7yrs | US$100.50k | 0.057% $ 11.8k | |
| Independent Director | 6yrs | US$111.00k | 0.0081% $ 1.7k | |
| Independent Director | 7.4yrs | US$105.00k | 0.091% $ 18.8k | |
| Independent Director | 10.3yrs | US$111.00k | geen gegevens |
8.2yrs
Gemiddelde duur
65yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van GLYC wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.2 jaar).